C2N Diagnostics Partners with BeauBrain Healthcare to Offer PrecivityAD2 Blood Test for Alzheimer’s Disease in South Korea

Why It Matters

The collaboration brings a highly accurate, minimally invasive Alzheimer’s diagnostic tool to South Korea, potentially accelerating early treatment and reducing reliance on costly imaging. It also signals growing global acceptance of blood‑based biomarkers for neurodegenerative diseases.

Key Takeaways

• C2N partners with BeauBrain to launch PrecivityAD2 in Korea
• Test shows 91% accuracy versus amyloid PET imaging
• FDA granted Breakthrough Device status to the blood test
• UK MHRA also approved the same diagnostic device
• Targets patients 50+ with mild cognitive impairment

Pulse Analysis

Blood‑based biomarkers are reshaping the Alzheimer’s diagnostic landscape, offering clinicians a less invasive, lower‑cost alternative to PET imaging. PrecivityAD2 leverages mass‑spectrometry to quantify amyloid‑beta isoforms and apolipoprotein E genotype, delivering results within hours. By entering the South Korean market through BeauBrain Healthcare, C2N taps into a rapidly aging population where early detection can dramatically influence care pathways and pharmaceutical uptake.

Robust clinical evidence underpins PrecivityAD2’s market entry. A JAMA study highlighted its superior diagnostic accuracy over standard clinical assessments, while npj Dementia demonstrated 91% overall accuracy, 90% sensitivity, and 92% specificity against amyloid PET, the current gold standard. These metrics suggest the test can reliably differentiate Alzheimer’s pathology from other dementias, reducing false‑positive referrals for expensive imaging and enabling timely therapeutic interventions.

Regulatory endorsements further accelerate adoption. The U.S. FDA’s Breakthrough Device designation fast‑tracks review, reflecting the test’s potential to address an unmet medical need. Concurrently, the UK’s MHRA granted medical device registration, establishing a precedent for European markets. In South Korea, the partnership aligns with national health policies promoting innovative diagnostics, positioning PrecivityAD2 as a cornerstone for future dementia care frameworks and opening avenues for broader regional expansion.